ASH Annual Meeting & Exposition CAR-T | Conference

Deepu Madduri, MD, on Next Steps for the CARTITUDE-1 Trial
January 18, 2021

The phase 1b/2 trial evaluated a single, low-dose infusion of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) in heavily pretreated patients with relapsed or refractory multiple myeloma.

Deepu Madduri, MD, on the Implications of the Phase 1b/2 CARTITUDE-1 Trial Results
January 14, 2021

Based on findings from the trial of ciltacabtagene autoleucel, further investigation of the therapy in other populations of patients with multiple myeloma is already underway.

Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 Trial
January 12, 2021

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

Deepu Madduri, MD, on the Results of the Phase 1b/2 CARTITUDE-1 Trial
January 11, 2021

The study was designed to evaluate the use of ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma in the United States.

Ide-Cel Improves HRQoL in Triple-Class Exposed Relapsed/Refractory Myeloma
December 07, 2020

Idecabtagene vicleucel yielded a clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.

Ide-cel Yields Deep, Durable Responses in Patients with Highly Refractory Myeloma
December 06, 2020

Patients with heavily pretreated multiple myeloma maintained durable responses with idecabtagene vicleucel, according to updated findings presented from the phase 1 CRB-401 trial.

Axicabtagene Ciloleucel Demonstrates Improved ORR in Indolent Non-Hodgkin Lymphoma
December 06, 2020

The CAR T-cell therapy elicited a 92% ORR, with high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

Odronextamab Shows Promise in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
December 06, 2020

A novel CD20xCD3 bispecific antibody, odronextamab, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

Cita-Cel Induces High Response Rate in Relapsed/Refractory Multiple Myeloma
December 06, 2020

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

Bijal D. Shah, MD, on CAR T-cell therapy and mantle cell lymphoma
December 30, 2019

Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.